Rachel Meyers joined Third Rock in 2018 as an entrepreneur-in-residence focusing on drug discovery and development opportunities across our portfolio.

Rachel brings to Third Rock 20 years of R&D leadership and operations experience. She joins us from Alnylam Pharmaceuticals (2003 – 2017), where she was most recently senior vice president of research and RNAi lead development. In this capacity, she played a key role in advancing RNAi therapeutic programs from early discovery through clinical development, and her team was responsible for program leadership for most of the company’s preclinical and clinical stage programs. She also had overall responsibility for the chemistry and platform technology efforts that are the underpinnings of the company’s pipeline. Before joining Alnylam in 2003, Rachel was a senior scientist at Millennium Pharmaceuticals (1999 – 2003) where she led a unit of the company’s target discovery and validation efforts involving bioinformatics and molecular and cell biology.

Rachel consults on RNAi therapies, serves on a number of Scientific Advisory Boards, is listed as an inventor in many patents and patent applications, and has published numerous peer-reviewed publications. She completed her postdoctoral training at Harvard Medical School in the field of signal transduction, and received her PhD from MIT in the field of in vitro transcription.

Rachel loves showtunes and musicals, teaching science to students of all ages, and competing in local and national squash tournaments.